沙利度胺、伊立替康和吉西他滨用于初治晚期非小细胞肺癌患者的II期试验
Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer.
作者信息
Jazieh A R, Komrokji R, Gupta A, Patil S, Flora D, Knapp M, Issa M, Abdel Karim N
机构信息
University of Cincinnati, Cincinnati, OH, USA.
出版信息
Cancer Invest. 2009 Nov;27(9):932-6. doi: 10.3109/07357900801944856.
This study aim was to determine the efficacy and safety of the combination of Gemcitabine 1000 mg/m(2) day 1 & 8 and Irinotecan 100 mg/m(2) day 1 & 8 with escalating dose of thalidomide in chemonaive patients with advanced non-small cell lung cancer. Among the 20 patients who met eligibility criteria and received treatment, two patients (10%) experienced partial response and 14 (70%) experienced stable disease. The median time to disease progression was 4 months (95% CI: 2.8-6.6). The 1 year and 2 year survival rates were 36% and 27%, respectively. This combination is active in advanced NSCLC with manageable toxicity profile.
本研究旨在确定吉西他滨1000mg/m²第1天和第8天、伊立替康100mg/m²第1天和第8天联合递增剂量沙利度胺用于初治晚期非小细胞肺癌患者的疗效和安全性。在符合入选标准并接受治疗的20例患者中，2例（10%）出现部分缓解，14例（70%）病情稳定。疾病进展的中位时间为4个月（95%CI：2.8 - 6.6）。1年和2年生存率分别为36%和27%。这种联合方案在晚期非小细胞肺癌中具有活性，且毒性特征可控。
Zotero 插件